| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lingnau Lutz |
Director |
– • – |
2017-07-14 |
4 |
AS |
$20.76 |
$622,800 |
D/D |
(30,000) |
23,450 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2017-07-14 |
4 |
OE |
$14.26 |
$427,800 |
D/D |
30,000 |
53,450 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-07-12 |
4 |
AS |
$21.09 |
$773,813 |
D/D |
(36,691) |
43,572 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-07-12 |
4 |
OE |
$11.04 |
$405,069 |
D/D |
36,691 |
80,263 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-07-11 |
4 |
AS |
$21.04 |
$176,505 |
D/D |
(8,389) |
43,572 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-07-11 |
4 |
OE |
$11.04 |
$92,615 |
D/D |
8,389 |
51,961 |
|
- |
|
| Krivulka Joseph J |
Director |
– • – |
2017-06-26 |
4 |
OE |
$8.37 |
$125,550 |
D/D |
15,000 |
73,000 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-06-07 |
4 |
AS |
$19.24 |
$1,956,708 |
D/D |
(101,700) |
227,243 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-06-07 |
4 |
OE |
$6.34 |
$951,000 |
D/D |
150,000 |
328,943 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-05-16 |
4 |
S |
$19.55 |
$163,985 |
D/D |
(8,388) |
160,884 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$51,827 |
D/D |
(2,651) |
52,986 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$62,149 |
D/D |
(3,179) |
66,091 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$33,255 |
D/D |
(1,701) |
32,803 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$57,848 |
D/D |
(2,959) |
60,689 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$28,348 |
D/D |
(1,450) |
43,572 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$61,504 |
D/D |
(3,146) |
178,943 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-05-15 |
4 |
AS |
$19.79 |
$98,950 |
D/D |
(5,000) |
271,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-05-15 |
4 |
OE |
$8.37 |
$41,850 |
D/D |
5,000 |
276,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-04-17 |
4 |
AS |
$18.72 |
$93,600 |
D/D |
(5,000) |
271,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-04-17 |
4 |
OE |
$8.37 |
$41,850 |
D/D |
5,000 |
276,623 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2017-04-07 |
4 |
AS |
$20.05 |
$140,350 |
D/D |
(7,000) |
23,450 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-04-05 |
4 |
AS |
$21.70 |
$3,906,000 |
D/D |
(180,000) |
63,648 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-04-05 |
4 |
OE |
$13.70 |
$2,466,000 |
D/D |
180,000 |
243,648 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-04-05 |
4 |
AS |
$21.70 |
$2,170,000 |
D/D |
(100,000) |
34,504 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-04-05 |
4 |
OE |
$9.53 |
$953,000 |
D/D |
100,000 |
134,504 |
|
- |
|
913 Records found
|
|
Page 20 of 37 |
|
|
